Uwe Himmelreich

Uwe Himmelreich Principal Investigator

Uwe Himmelreich (°1965) has studied physical chemistry. He has more than 25 years of research experience in magnetic resonance imaging and spectroscopy. He is the coordinator of the KU Leuven core facility MoSAIC with approximately 150 users. He is currently the promoter of 9 PhD students. His expertise is in the development of novel, multi-modal in vivo imaging approaches in preclinical research. Hereby, the focus is on the non-invasive characterization of experimental disease and treatment models, including in neurodegeneration (Alzheimer’s, Parkinson’s disease, ALS), infectious diseases (fungal infections) and oncology. He has a strong interest in the development and validation of new contrast agents for in vivo cell imaging and potential theranostic applications. This includes nanoparticles for the validation of novel approaches in treatment monitoring and nanoparticles for theranostic applications. Hereby, he tries to combine different imaging modalities (MRI, PET, CT, OI) to overcome limitations of individual methods. He has published more than 200 papers in peer-reviewed journals.

The Organization

The University of Leuven (KU Leuven) was founded 1425 and is the oldest university in the Low Countries. At present, KU Leuven caters to more than 41,000 students, around 16% of whom are international students from more than 120 nations. In terms of its personnel, there are 1,495 senior and 5,523 junior academic staff, 3,371 administrative and technical staff, and 8,892 university hospital staff members. The university is composed of fourteen faculties, fifty departments and about 240 sub-departments. Concerning its medical facilities, KU Leuven supports five hospitals and three affiliated hospitals, with a total of more than 2,000 hospital beds. KU Leuven is an internationally oriented, research intensive university focusing both on fundamental and applied research. Counting over 100 spin-off companies, it furthermore has an extensive track record in tech transfer of its research results.

The Biomedical MRI at the KU Leuven core facility MoSAIC focuses on the in vivo characterization of experimental disease and treatment models. Hereby, we make use of all state-of-the-art in vivo imaging modalities. Our infrastructure includes a 9.4T MRI scanner (Bruker Biospec), a PET scanner (Focus 220), a 7T PET/ MRI scanner (Bruker Biospec/ Albeira) CT scanners (Skyscan 1076 and Skyscan 1278), ultrasound scanners (Visualsonics), optical imaging instrumentation (IVIS Spectrum from Perkin Elmer, IVM from Cellvizio and OCT from AGFA), phase contrast imaging (Carestream) and others. Matching clinical infrastructure is available as we are based on the campus of the University Hospital Leuven. Our research also involves the development and validation of contrast agents (mainly nanoparticles) and tracers (GMP cyclotron on campus).


People Involved

Uwe Himmelreich Position Professor and Head of Biomedical MRI, Department of Imaging and Pathology. Head of the core facility MoSAIC. Role in PANA Principal Investigator
Willy Gsell Position MRI lab manager Role in PANA Development of in vivo imaging protocols
Stefaan Soenen Position Senior postdoc Role in PANA Nanoparticle characterization/ toxicity
Rita Sofia Garcia Ribeiro Position PhD student Role in PANA Magnetoliposome synthesis
Kristof Govaerts Position PhD student Role in PANA Alzheimer’s disease models
This project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 686009


Clinical Neuroscience Research Laboratory
University Clinical Hospital Santiago
A Building, -4 Floor
E15706 A Coruña, Spain
View map

At we use own and third party cookies to offer you a better service and obtain anonymous statistical data. If you continue browsing we consider that you accept its use. You can get more information, or how to change your settings in our cookies policy.